ArticleScientific reports2025
DFT supported computational insights into Withaferin A structure and its binding interaction with Hsp90.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Breast Cancer: Epidemiology, Molecular Classification, Diagnostics and Evolving Treatment Paradigms.Molecules (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Withaferin A, a bioactive steroidal lactone, was systematically investigated using density functional theory (DFT) and complementary computational approaches to understand its structural stability, electronic reactivity, and therapeutic potential. The combined spectroscopic and electronic analyses confirmed strong electron delocalization, stable molecular configuration, and favorable charge-transfer characteristics. Natural bond orbital and frontier molecular orbital studies revealed extensive hyperconjugation and high kinetic stability, while thermodynamic assessments indicated spontaneous and stable behavior across varying temperatures. Molecular docking with Hsp90 demonstrated strong binding affinity, stabilized by hydrogen bonding and Van der Waals interactions with key residues. These findings highlight Withaferin A’s structural robustness, electronic versatility, and potent binding characteristics, supporting its promise as a therapeutic inhibitor. Overall, this integrative computational study provides valuable molecular-level insights that can guide future experimental validation and rational drug design involving Hsp90-targeted compounds.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.